Dr Mario Polywka is an Industry Adviser to MCF Corporate Finance. He holds a bachelor’s degree in PhD in Organic Chemistry from University of Oxford. Mario was a founding chemist of Oxford Asymmetry International and part of the executive team that took the company public in 1998. Previously, he served as CEO when the company was acquired by Evotec Biosystems in 2000 to form what is now Evotec SE. Apart from a spell in 2002-2004, when he helped spin out companies from Oxford University, he remained with Evotec, retiring as COO in 2018. Mario now serves on the Supervisory Board of Evotec SE, and is a non-executive director on the Boards of Exscientia Ltd, Forge Therapeutics Inc, Orbit Discovery Ltd, Blacksmith Medicines Inc, and C4X Discovery PLC.
Expertise
- Biotech
Dr Mario Polywka is an Industry Adviser to MCF Corporate Finance. He holds a bachelor’s degree in PhD in Organic Chemistry from University of Oxford. Mario was a founding chemist of Oxford Asymmetry International and part of the executive team that took the company public in 1998. Previously, he served as CEO when the company was acquired by Evotec Biosystems in 2000 to form what is now Evotec SE. Apart from a spell in 2002-2004, when he helped spin out companies from Oxford University, he remained with Evotec, retiring as COO in 2018. Mario now serves on the Supervisory Board of Evotec SE, and is a non-executive director on the Boards of Exscientia Ltd, Forge Therapeutics Inc, Orbit Discovery Ltd, Blacksmith Medicines Inc, and C4X Discovery PLC.